TREAT-AD is partnering with YCharOS to provide antibody characterization for understudied AD targets. Learn why YCharOS’s CSO Carl Laflamme says “the most cited antibodies are not necessarily the best antibodies.”
The Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) consortium discussed their goals, including the development of new models based on recent human genetics, the alignment of AD pathophysiology in mouse models and human studies, the staging of disease progression, and preclinical testing based on translatable biomarkers.
Dr. Gregory Carter is an Associate Professor at The Jackson Laboratory, Bar Harbor, ME. He combines genetic, genomic, imaging, and other data resources to understand the causes and progression of Alzheimer’s disease.